Pichia pastoris To Enhance G-Protein ... - ACS Publications

Subscriber access provided by ORTA DOGU TEKNIK UNIVERSITESI KUTUPHANESI

Letter

Modular integrated secretory system engineering in Pichia pastoris to enhance G-protein coupled receptor expression. Katrien Claes, Kristof Vandewalle, Bram Laukens, Toon Laeremans, Olivier Vosters, Ingrid Langer, Marc Parmentier, Jan Steyaert, and Nico Callewaert ACS Synth. Biol., Just Accepted Manuscript • DOI: 10.1021/acssynbio.6b00032 • Publication Date (Web): 13 May 2016 Downloaded from http://pubs.acs.org on May 15, 2016

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

ACS Synthetic Biology is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 18

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ACS Synthetic Biology

Modular integrated secretory system engineering in Pichia pastoris to enhance G-protein coupled receptor expression. Katrien Claes1,2,°, Kristof Vandewalle1,2,°, Bram Laukens1,2, Toon Laeremans3,4, Olivier Vosters5, Ingrid Langer5, Marc Parmentier5,6, Jan Steyaert3,4 and Nico Callewaert1,2*

1

Unit for Medical Biotechnology, Medical Biotechnology Center, VIB, Technologiepark 927,

9052 Ghent, Belgium. 2

Laboratory for Protein Biochemistry and Biomolecular Engineering, Department of

Biochemistry and Microbiology, Ghent University, K.L.-Ledeganckstraat 35, 9000 Ghent, Belgium. 3

Structural Biology Research Center, VIB, Pleinlaan 2, 1050 Brussels, Belgium.

4

Structural Biology Brussels, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.

5

Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM),

Campus Erasme, 808 Route de Lennik, B-1070 Brussels, Belgium. 6

Welbio, Université Libre de Bruxelles (U.L.B.), Campus Erasme, 808 Route de Lennik, B-

1070 Brussels, Belgium.

°These authors contributed equally to this study. *

Correspondence should be addressed to N.C. ([email protected])

Email addresses: KC: [email protected] KV: [email protected] BL: [email protected] TL: [email protected] OV: [email protected] IL: [email protected] MP: [email protected] JS: [email protected] NC: [email protected]

1 ACS Paragon Plus Environment


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 2 of 18


Page 3 of 18

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Keywords Pichia pastoris, membrane protein expression, CXCR4, Nanobodies, N-Glycosylation

Abstract Membrane protein research is still hampered by the generally very low levels at which these proteins are naturally expressed, necessitating heterologous expression. Protein degradation, folding problems and undesired post-translational modifications often occur, together resulting in low expression levels of heterogeneous protein products that are unsuitable for structural studies. We here demonstrate how the integration of multiple engineering modules in Pichia pastoris can be used to increase both the quality and the quantity of overexpressed integral membrane proteins, with the human CXCR4 G-protein coupled receptor as an example. The combination of reduced proteolysis, enhanced ER folding capacity, GlycoDeletebased N-Glycan trimming and Nanobody-based fold stabilization improved the expression of this GPCR in P. pastoris from a low expression level of a heterogeneously glycosylated, proteolysed product to substantial quantities (2-3 mg/l shake flask culture) of a non-proteolysed, homogenously glycosylated proteoform. We expect that this set of tools will contribute to successful expression of more membrane proteins in a quantity and quality suitable for functional and structural studies.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 4 of 18

Many proteins reside within the plasma membrane and intracellular membranes of the cell, establishing communication with the environment and subcellular compartments. This is achieved through transporters, receptors, enzymes and anchoring proteins. Because of these essential functions and the accessibility of many of these proteins from the outside of the cell, they are targeted by over 50% of the currently prescribed drugs1. Furthermore, for drug discovery research in the membrane protein field, the availability of expression host cells that can produce the drug target at high levels in a homogenous fashion is of paramount importance. Such cells are used for direct drug screening2. Many drugs have severe side effects or have to be administered in high doses because they are not selective, nor potent enough1. One way to improve this is to perform structure based drug design, but there are still much fewer membrane protein 3D structures as compared to soluble proteins. This is in part because the natural abundance of membrane proteins in native tissue is most often low and therefore, recombinant production is needed. Overexpression and purification of membrane proteins is very challenging and it is essential to express the protein in an as natural and homogeneous conformation as possible. Both the quality and quantity of the heterologously expressed membrane protein is crucial3. Heterogeneity due to glycosylation, proteolysis, or different conformational states can severely hamper crystal growth. Furthermore, in order to test many different crystallization conditions, milligram amounts of membrane protein are generally required4. While these amounts are slowly dropping due to robotics that can handle nano- to picoliter volumes5, many of the more difficult membrane proteins are still way out of reach. In this contribution, we used the human G-protein coupled receptor (GPCR) CXCR4 as a case study membrane protein to investigate the effects of several yeast secretory system engineering modules. The receptor is naturally expressed on CD4+ T cells and is, together with CCR5, especially known as one of the primary coreceptors for HIV viral infection6. GPCRs in general consist of seven membrane spanning helices, connected by intracellular and extracellular loops. They can bind molecules on the outside of the cell and then change conformation to activate a signalling cascade inside the cell, resulting in a cellular response. GPCRs are involved in many key physiological functions and in multiple diseases, such as neurodegenerative disorders and cancer. They are of great clinical importance7 and it is not surprising that GPCRs are still amongst the most researched proteins in the pharmaceutical industry. A major breakthrough in GPCR structure determination was the discovery that a T4 lysozyme insertion, in the place of the flexible third internal 4 ACS Paragon Plus Environment

Page 5 of 18

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


loop of several A-class GPCRs, protected the receptors from proteolytic degradation and provided a larger hydrophilic interface during crystallization8. Except for the first characterized GPCR structure of bovine rhodopsin9, almost all GPCR crystal structures that have been solved today were obtained using the T4 lysozyme insertion strategy8,10–13. However, the vast majority of this class of receptors still remains intractable from a heterologous expression point of view. Even for those membrane proteins that express relatively well and could be successfully purified and crystallized, most often extensive protein engineering through e.g. N- and Cterminal truncations and stabilizing mutations was required8,10–13. In this contribution, we focused on the modular engineering of the expression host rather than of the expressed membrane protein (Figure 1). We codon-optimized the human CXCR4 receptor gene to facilitate heterologous expression in Pichia pastoris, and N-terminally fused it to the Saccharomyces cerevisiae alpha mating factor prepro-signal to direct the protein to the ER membrane. We added a C-terminal Rho1D4 tag for easy detection and put the gene under control of the inducible AOX1 promoter. Upon expression of the human CXCR4 receptor in the GS115 background, it was clear that the protein was sensitive to N-terminal degradation. The electrophoretic mobility of the receptor is somewhat faster than the mobility of soluble globular standard proteins of 40 kDa (Figure 2). As overexpressed membrane proteins in yeast likely will be distributed over multiple compartments of the cell (ER, Golgi, plasma membrane, endosomes and vacuole) for prolonged periods of time, we reasoned that exposure to vacuolar proteases would be the main reason for the observed degradation of yeast-expressed membrane proteins. Proteinase A is an aspartic proteinase that is produced as a zymogen and can auto-activate itself under acidic pH14. In turn, it activates a whole array of other vacuolar proteases and is therefore a good target for reducing vacuolar proteolysis15. By changing to the SMD1168 host strain (his4 ∆pep4), which lacks the vacuolar proteinase A, higher molecular weight species were produced, but in a much more heterogeneous fashion (Figure 1 and Figure 2, lane 1 vs. lane 2), which is indicative for heterogeneous glycosylation. Indeed, many GPCR’s, including CXCR4, are N-glycosylated on sites in the N-terminal luminal sequence. This glycosylation site (Asn15 for CXCR4) is expectedly deleted in the N-terminally proteolyzed protein, as obtained from the wild type Pichia cells, hence the absence of this smear. Indeed, this hypothesis was confirmed upon PNGaseF digestion of the ∆pep4 expressed membrane proteins, which converted the smear to a tight band at the approximate expected molecular weight for this GPCR (Figure 2, lane 2 vs. lane 5 ACS Paragon Plus Environment


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 6 of 18

5). To counteract this N-glycosylation-introduced heterogeneity, we implemented a yeast version of our recently developed GlycoDelete engineering strategy16, which involves simultaneous expression of the fungal endoglycosidase endoT (manuscript in preparation). EndoT cleaves the N-glycosylation structures between the proteinproximal two N-acetyl glucosamine (GlcNAc) residues, leaving a single GlcNAc on the asparagine residue16,17. Figure 2 demonstrates similar homogeneity of the CXCR4 receptor in the GlycoDelete ∆pep4 strain as for protein produced in the ∆pep4 strain upon in vitro PNGase F de-N-glycosylation (Figure 2 lane 4 vs. lane 5). In addition, the small remainder of proteolysis in the ∆pep4 strain also appears to be absent in the GlycoDelete ∆pep4 strain (Figure 2 lane 4 vs. lane 2 and 5). A PNGase F treatment on the GlycoDelete ∆pep4 membrane protein extract does not further change the profile (Figure 2 lane 5 and 6), providing evidence that the GlycoDeletemediated deglycosylation of the CXCR4 receptor is complete. Together, the ∆pep4 and GlycoDelete engineering modules lead to expression of this membrane protein in a very homogeneous, undegraded quality. After establishing enhanced protein homogeneity, we further implemented modules to increase the amount of produced membrane protein. First, we co-expressed the spliced form of HAC1 in the GlycoDelete ∆pep4 CXCR4 strain to induce the unfolded protein response (UPR) upon methanol induction18. This resulted in a modest 59% increase of expressed membrane protein (Figure 3a, lane 1 vs. lane 2). In a previous contribution18, we also showed that HAC1 overexpression did not dramatically increase expression levels of another GPCR (adenosine A2A receptor), but strongly improved receptor ligand binding activity, most likely through enhanced folding caused by improved chaperone activity in combination with effective degradation of incorrectly folded molecules. We have tried to perform radio-ligand binding assays using the tritiated CXCR4 agonist chemokine SDF1α on crude P. pastoris membrane extracts. However, we encountered an excessively high background signal (aspecific binding of the ligand) in strain extracts not containing the receptor, and therefore were unable to proceed with these experiments. However, the enhanced expression of this receptor in the face of enhanced ER-associated degradation (ERAD) capacity for misfolded proteins, is evidence for the natively folded state of the receptor in our strains. In addition to UPR induction, we wanted to test whether co-expression of CXCR4specific Nanobodies as protein-specific chaperones would further enhance expression levels by stabilizing the receptor. Because Nanobodies express at very high levels in Pichia and the bulk of these molecules get secreted, a high 6 ACS Paragon Plus Environment

Page 7 of 18

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


concentration should be continuously present in the yeast’s secretory system, available for binding and stabilizing the CXCR4 receptor. To this end, two llamas were immunized with either intact Chinese hamster ovary cells (CHO-K1 cells) overexpressing the CXCR4 receptor, or with membranes derived from these cells. Nanobody-encoding open reading frames were then amplified from the cDNA of the peripheral blood lymphocytes and cloned into phage display libraries19. The resulting libraries were enriched for CXCR4-specific Nanobodies by several rounds of panning against CXCR4-expressing CHO-K1 cells and against CHO-K1 membrane extracts. Finally, binding of eight individually purified Nanobodies to the extracellular domain of the CXCR4 receptor was analyzed by FACS analysis. To this end, CHO cells with and without CXCR4 were incubated with His6-tagged Nanobodies and the cells were stained with Alexa Fluor® 647-conjugated anti-His6 mAb. The fluorescence intensity shift between CXCR4 expressing and non-expressing CHO cells, as determined via flow cytometry was used as a measure of specific binding of the Nanobody to the extracellular side of the receptor (Supplementary Table S2). We tested these eight Nanobodies, binding to the extracellular region of CXCR4, and one control Nanobody, recognizing another GPCR (ChemR23) for their capacity to enhance CXCR4 expression (Supplementary Figure S1). From this set of Nanobodies, co-expression of NbCA4139 with the receptor consistently showed the highest increase in expression yield: we observe a 2- to 3-fold increase in CXCR4 expression levels (Figure 3a, lane 1 vs. lane 3). Co-expression of the control Nanobody induced no increase in CXCR4 receptor expression levels (Figure 3a lane 1 vs. lane 5). In two functional assays, Nanobody NbCA4139 inhibited receptor binding of the CXCL12 ligand (Supplementary Figure S2 and Table S2). This Nanobody was raised against the CXCR4 receptor functionally expressed in mammalian cells, and inhibits ligand binding in functional assays in mammalian cells. Its co-expression with the receptor in yeast strongly enhances the production level of the receptor. This again provides evidence that the CXCR4 receptor in yeast is natively folded, as no such effects would be expected if the conformational epitope for the Nanobody were not present. Finally, as Nanobodies are massively expressed in Pichia pastoris, we wanted to exclude that the observed expression-improvement is due to unfolded protein response secretory system overload. To this end, we performed a quantitative RTPCR experiment on the KAR2 UPR sentinel gene20. KAR2 encodes a molecular chaperone responsible for assistance in protein folding. We tested UPR-induction for 7 ACS Paragon Plus Environment


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 8 of 18

the different engineered strains in four independent experiments. From Figure 4 it is clear that upon HAC1 expression (i.e. the driving transcription factor for UPR), the UPR is induced, as expected. However, neither the GlycoDelete module nor expression of the anti-CXCR4 Nanobody induced UPR. We therefore conclude that the Nanobody-induced enhanced receptor expression level is not caused by an induction of the unfolded protein response, but suggest that it is due to a specific stabilization of the receptor, during or after protein folding at the ER membranelumen interface. These data suggested that Nanobody co-expression and HAC1mediated UPR induction could act synergistically on the expression level. Indeed, upon combining the HAC1 and receptor-specific Nanobody co-expression modules, a 4- to 5-fold increase in CXCR4 expression could be obtained as compared to the GlycoDelete ∆pep4 CXCR4 strain (Figure 3a: lane 1 vs. lane 4, and Figure 3b). By using a Rho1D4-tagged IL-22 internal standard on Western blot, we estimated the total amount of CXCR4 in this final strain (∆pep4 CXCR4 Hac1 NbCA4139) at 2-3 mg per 125 mg (± 2%) of total membrane protein per liter of Pichia shake flask culture (Supplementary Figure S3). This is a level that is a feasible starting point for extraction and purification purposes. For comparison, the most easily expressed GPCR, bovine rhodopsin, which was also the first one to be crystallized, can be produced at ± 2 – 5 mg per liter of highly optimized HEK293 suspension cell culture21. With this synthetic biology study we showcase the development and integration of a panel of engineering modules for Pichia pastoris that increase the chances for difficult-to-express membrane proteins, using the model CXCR4 G-protein coupled receptor, to reach the quantity and quality needed to allow for use of the cells in drug screening projects and/or for starting up structure determination projects. The application of this set of engineering modules may provide powerful tools to explore the expression in sufficient quantity and quality of eukaryotic membrane proteins in Pichia pastoris, an expression system that in and by itself is already one of the more successful ones for the expression of membrane proteins22. As GPCR stabilization can also be achieved by T4 lysozyme insertion in the third intracelullar loop, it would be useful in future work to explore whether this could replace the Nanobody coexpression in our approach. However, for other categories of membrane proteins, Nanobody co-expression provides for a potentially more broadly applicable stabilization strategy. Contrary to other methods for enhancing membrane protein expression, it is of note that for our methodology, nothing needs to be changed in the protein’s native sequence, which should be useful to pharmacologists. 8 ACS Paragon Plus Environment

Page 9 of 18


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 10 of 18

Materials and methods Full details of all materials and methods are provided in online Supporting Information.

Competing interests The authors declare to have no competing financial interests.

Authors' contributions KC and KV designed and performed experiments, analyzed and interpreted data and drafted the manuscript. BL developed the GlycoDelete system in Pichia pastoris. TL generated the CXCR4 Nanobodies under scientific supervision of JS. OV and IL characterized the Nanobodies under supervision of MP. NC initiated and designed the study, coordinated the project, interpreted data and co-wrote the manuscript. All authors read and approved the final version of the manuscript.

Acknowledgements KC and BL are supported by a Ph.D. grant from the Institute for the Advancement of Scientific and Technological Research in Industry (IWT–Vlaanderen). KV is supported by the Fund for Scientific Research Flanders (FWO). JS & NC thank INSTRUCT, part of the European Strategy Forum on Research Infrastructures (ESFRI) and the Hercules Foundation Flanders for their support to Nanobody discovery. Research in the lab of JS is also supported by G049512N of the Fund for Scientific Research Flanders (FWO). Research in the lab of MP is supported by the Brussels Region (3D4Health program), the Fonds de la Recherche Scientifique Médicale of Belgium and the Interuniversity Attraction Poles Programme (P7–14), Belgian State, Belgian Science Policy. Research in the lab of NC is supported by the Marie Curie Excellence Grant MEXT-014292 under EU Framework Program 6 and Research grant G.0.541.08.N.10 of the Fund for Scientific Research Flanders (FWO).

Associated content Supporting information Figure S1: Effect of CXCR4 expression level upon specific Nanobody coexpression, Figure S2: Functional characterization of the CXCR4-specific Nanobody and the control Nanobody, Figure S3: Quantification of the CXCR4 expression level. Table S1: Coding sequences of the CXCR4-specific and control Nanobody, Table S2: Summary of the Nanobody – CXCR4 binding data, Table S3: Primers used for UPR10 ACS Paragon Plus Environment

Page 11 of 18

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


detection in quantitative PCR experiment. Material and methods. Supplementary references.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 12 of 18

References (1) Overington, J. P., Lazikani, B. Al-, and Hopkins, A. L. (2006) How many drug targets are there? Nat Rev Drug Discov 5, 993–996. (2) Liu, R., Wong, W., and IJzerman, A. P. (2016) Human G protein-coupled receptor studies in Saccharomyces cerevisiae. Biochem. Pharmacol. (3) Baker, M. (2010) Making membrane proteins for structures: a trillion tiny tweaks. Nat Meth 7, 429–434. (4) Carpenter, E. P., Beis, K., Cameron, A. D., and Iwata, S. (2008) Overcoming the challenges of membrane protein crystallography. Curr Opin Struct Biol 18, 581–586. (5) Zhu, Y., Zhu, L.-N., Guo, R., Cui, H.-J., Ye, S., and Fang, Q. (2014) Nanoliter-Scale Protein Crystallization and Screening with a Microfluidic Droplet Robot. Sci. Rep. 4. (6) Berson, J. F., and Doms, R. W. (1998) Structure–function studies of the HIV-1 coreceptors. Seminars in Immunology 10, 237–248. (7) Katritch, V., Cherezov, V., and Stevens, R. C. (2012) Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol. Sci. 33, 17–27. (8) Rosenbaum, D. M., Cherezov, V., Hanson, M. A., Rasmussen, S. G. F., Thian, F. S., Kobilka, T. S., Choi, H.-J., Yao, X.-J., Weis, W. I., Stevens, R. C., and Kobilka, B. K. (2007) GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function. Science 318, 1266–1273. (9) Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289, 739–745. (10) Wu, B., Chien, E. Y. T., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Brooun, A., Wells, P., Bi, F. C., Hamel, D. J., Kuhn, P., Handel, T. M., Cherezov, V., and Stevens, R. C. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066–1071. (11) Haga, K., Kruse, A. C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C., Weis, W. I., Okada, T., Kobilka, B. K., Haga, T., and Kobayashi, T. (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547–551. (12) Zhang, C., Srinivasan, Y., Arlow, D. H., Fung, J. J., Palmer, D., Zheng, Y., Green, H. F., Pandey, A., Dror, R. O., Shaw, D. E., Weis, W. I., Coughlin, S. R., and Kobilka, B. K. (2012) High-resolution crystal structure of human protease-activated receptor 1. Nature 492, 387– 392. (13) Serrano-Vega, M. J., and Tate, C. G. (2009) Transferability of thermostabilizing mutations between beta-adrenergic receptors. Mol. Membr. Biol. 26, 385–396. (14) Parr, C. L., Keates, R. A. B., Bryksa, B. C., Ogawa, M., and Yada, R. Y. (2007) The structure and function of Saccharomyces cerevisiae proteinase A. Yeast 24, 467–480. (15) Wu, M., Shen, Q., Yang, Y., Zhang, S., Qu, W., Chen, J., Sun, H., and Chen, S. (2013) Disruption of YPS1 and PEP4 genes reduces proteolytic degradation of secreted HSA/PTH in Pichia pastoris GS115. J Ind Microbiol Biotechnol 40, 589–599. (16) Meuris, L., Santens, F., Elson, G., Festjens, N., Boone, M., Santos, A. Dos, Devos, S., Rousseau, F., Plets, E., Houthuys, E., Malinge, P., Magistrelli, G., Cons, L., Chatel, L., Devreese, B., and Callewaert, N. (2014) GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins. Nat Biotech 32, 485–489. (17) Stals, I., Samyn, B., Sergeant, K., White, T., Hoorelbeke, K., Coorevits, A., Devreese, B., Claeyssens, M., and Piens, K. (2010) Identification of a gene coding for a deglycosylating enzyme in Hypocrea jecorina. FEMS Microbiol. Lett. 303, 9–17. (18) Guerfal, M., Ryckaert, S., Jacobs, P. P., Ameloot, P., Van Craenenbroeck, K., Derycke, R., and Callewaert, N. (2010) The HAC1 gene from Pichia pastoris: characterization and


Page 13 of 18

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


effect of its overexpression on the production of secreted, surface displayed and membrane proteins. Microb Cell Fact 9, 49–49. (19) Pardon, E., Laeremans, T., Triest, S., Rasmussen, S. G. F., Wohlkönig, A., Ruf, A., Muyldermans, S., Hol, W. G. J., Kobilka, B. K., and Steyaert, J. (2014) A general protocol for the generation of Nanobodies for structural biology. Nat. Protocols 9, 674–693. (20) Kimata, Y., Kimata, Y. I., Shimizu, Y., Abe, H., Farcasanu, I. C., Takeuchi, M., Rose, M. D., and Kohno, K. (2003) Genetic Evidence for a Role of BiP/Kar2 That Regulates Ire1 in Response to Accumulation of Unfolded Proteins. Mol Biol Cell 14, 2559–2569. (21) Reeves, P. J., Kim, J.-M., and Khorana, H. G. (2002) Structure and function in rhodopsin: a tetracycline-inducible system in stable mammalian cell lines for high-level expression of opsin mutants. Proc. Natl. Acad. Sci. U.S.A. 99, 13413–13418. (22) Lundstrom, K., Wagner, R., Reinhart, C., Desmyter, A., Cherouati, N., Magnin, T., ZederLutz, G., Courtot, M., Prual, C., André, N., Hassaine, G., Michel, H., Cambillau, C., and Pattus, F. (2006) Structural genomics on membrane proteins: comparison of more than 100 GPCRs in 3 expression systems. J Struct Funct Genomics 7, 77–91.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 14 of 18

Figure legends

Figure 1. Concept of the modular integrated secretory system engineering of Pichia pastoris to enhance membrane protein expression. A. In a wild type Pichia cell, the nascent membrane protein chain is inserted in the endoplasmic reticulum (ER), where it is decorated with N-glycan moieties. However, because of the high protein load, folding problems can result in degradation of the membrane proteins through the ER protein quality control machinery. When the correctly folded proteins are transported to the Golgi, multiple glycosyltransferases extend the glycan tree, which generates a heterogeneous membrane protein population. Further membrane protein transport is either directly to the plasma membrane, or to the vacuole, where it can be degraded due to the presence of vacuolar proteases. Therefore, expression of membrane proteins in the wild type cell generally results in low quantities of partially degraded, heterogeneous membrane protein. B. By modular engineering of Pichia, we were able to counteract the main problems 14 ACS Paragon Plus Environment

Page 15 of 18

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


encountered in the cell. Module 1: Induction of the unfolded protein response (UPR) increases the cell’s capacity to deal with high rates of protein synthesis. Module 2: Higher membrane protein expression levels are obtained by co-expression of Nanobodies (red ovals), which act as protein-specific chaperones. Module 3: Implementation of the GlycoDelete technology results in efficient trimming of the Nglycan, generating a homogenous protein sample with a single N-acetyl-glucosamine residue (black square). Module 4: Expression in the protease deficient strain, ∆pep4, strongly reduces proteolysis. In conclusion, production in the modular secretory system engineered strain, results in substantial quantities of intact, homogeneous membrane protein.

Figure 2. Quality improvement of the expressed membrane protein. By shifting the expression background for the CXCR4 receptor from wild type GS115 (lane 1) to the protease deficient P. pastoris strain, ∆pep4 (lane 2), a higher amount of the receptor with an intact N-terminus, but still heterogeneous N-glycans, can be observed. To increase the homogeneity of the sample, the receptor was expressed in the GlycoDelete strain (lane 3) and in the GlycoDelete ∆pep4 strain (lane 4). This results in membrane proteins that are decorated with a single N-acetyl glucosamine residue (GlcNAc). Expression of the GPCR in the GlycoDelete ∆pep4 strain, strongly improves the quality of the CXCR4 receptor. The presence of N-glycans on the receptor of the ∆pep4 strain (lane 5) and the GlycoDelete ∆pep4 strain (lane 6) was 15 ACS Paragon Plus Environment


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 16 of 18

confirmed by treating the membrane protein samples with PNGaseF.

Figure 3. Quantitative improvement of the expressed membrane protein. a. Western blot analysis showing the expression level increase of CXCR4, starting from the GlycoDelete ∆pep4 strain (lane 1). Upon co-expression of HAC1 (lane 2) and Nanobody 39 (lane 3) an increase in expression levels can be observed, with an even higher increase upon combining both strategies (lane 4). Co-expression of the control Nanobody directed against another GPCR did not increase the expression level of the CXCR4 receptor. b. Expression levels of three independent biological replicates, quantified using the Odyssey system. A total 4- to 5-fold enhancement of membrane protein expression could be obtained.


Page 17 of 18

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 4. Quantitative PCR analysis of the unfolded protein response. Four biological replicates in the early exponential phase were analyzed for induction of the unfolded protein response. The strains expressing HAC1 show an increase in mRNA levels of HAC1 and KAR2, the signature gene of the unfolded protein response. Because KAR2 transcription is not increased in the Nanobody co-expressing strain, the enhanced CXCR4 (CR) expression levels seen when co-expressing the Nanobody are not due to UPR induction. Statistical analysis is performed using the Prism6 software.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

1066x639mm (120 x 120 DPI)

ACS Paragon Plus Environment

Page 18 of 18

Pichia pastoris To Enhance G-Protein ... - ACS Publications

Recommend Documents